CN105560585A - New application of solanum lyratum to preparation of medicine for treating hyperlipidemia - Google Patents

New application of solanum lyratum to preparation of medicine for treating hyperlipidemia Download PDF

Info

Publication number
CN105560585A
CN105560585A CN201610098221.6A CN201610098221A CN105560585A CN 105560585 A CN105560585 A CN 105560585A CN 201610098221 A CN201610098221 A CN 201610098221A CN 105560585 A CN105560585 A CN 105560585A
Authority
CN
China
Prior art keywords
herba solani
solani lyrati
extract
ethanol
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201610098221.6A
Other languages
Chinese (zh)
Inventor
覃济桓
刘冠萍
郑志远
梁云飞
林艳英
黄源春
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangxi Wuzhou Pharmaceutical Group Co Ltd
Original Assignee
Guangxi Wuzhou Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangxi Wuzhou Pharmaceutical Group Co Ltd filed Critical Guangxi Wuzhou Pharmaceutical Group Co Ltd
Priority to CN201610098221.6A priority Critical patent/CN105560585A/en
Publication of CN105560585A publication Critical patent/CN105560585A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention relates to new application of solanum lyratum, namely new application of solanum lyratum to preparation of medicine for treating hyperlipidemia, in particular to new application of solanum lyratum aqueous extract and lyratum thunb alcohol extract to preparation of medicine for treating hyperlipidemia.

Description

The novelty teabag of Herba Solani Lyrati in preparation treatment hyperlipidemia medicine
Technical field
The present invention relates to Herba Solani Lyrati at the novelty teabag, particularly Herba Solani Lyrati water extract prepared in hyperlipidemia medicine and the novelty teabag of Herba Solani Lyrati ethanol extract in preparation hyperlipidemia medicine.
Background technology
Hyperlipidemia is the main inducing of various cardiovascular disease, the infringement of this disease to health be concealment, gradually, Progressive symmetric erythrokeratodermia and general.Along with rising and the prolongation of dyslipidemia time of blood fat, it can cause the various diseases such as atherosclerosis, coronary heart disease, hypertension, diabetes, apoplexy, fatty liver.The sickness rate of these cardiovascular and cerebrovascular diseases is high, and harm is large, and disease progression is dangerous, about its mortality rate accounts for the half of mankind's general mortality rate.According to the display of epidemiology statistics data, the normal population that the probability suffering from people with hyperlipidemia morbidity was not organized than the same age is high, and its sickness rate will exceed 4 times.
Along with improving constantly of people's living standard, dyslipidemia also will present obvious growth trend.Hyperlipidemia sickness rate in the middle of middle-aged and elderly people is high, and along with China steps into aging society, the sickness rate of hyperlipidemia increases day by day, becomes an important content in China's Healthcare gradually.The continuous increase of people with hyperlipidemia, and people are to the raising of its recognizing dangers, constantly expand, attract people's attention to the demand of blood lipid-lowering medicine, blood lipid-lowering medicine remains the quick growing trend of annual 9%.Therefore, research and develop novel blood lipid-lowering medicine and there is great Social benefit and economic benefit.
At present, the medicine being used for the treatment of dyslipidemia clinically comprises: Statins, shellfish special class, nicotinic acid class, resinae, cholesterol absorption inhibitor and antioxidant.But these medicines all have side effect in various degree, especially calendar year 2001 visit sthene in 1997 listing after, the whole world has 52 examples and visits sthene cause rhabdomyolysis, destroyed muscle cell to cause the exhaustion of renal function thus the report of causing death by renal excretion because taking, the generation of all untoward reaction, the untoward reaction of people to Western medicine is worried more, patient dependence declines, and have impact on the normal therapeutic of hyperlipidemia patient.
But the side effect for the treatment of by Chinese herbs disease is little, and untoward reaction is few, compared with chemical drugs more compatriots accepted.Though the traditional Chinese medical science is without the name of disease of hyperlipidemia, the cause of disease produced according to hyperlipidemia, pathogenic characteristic and associated diseases, the expectorant that can be summarized as the traditional Chinese medical science is turbid, blood stasis, carries out determination for the treatment of based on pathogenesis obtained through differentiation of symptoms and signs.
Herba Solani Lyrati is cold in nature, sweet in the mouth, nontoxic, is usually used in treatment icterohepatitis, cholecystitis, cholangitis, cholelithiasis, metabolism syndrome etc., does not have documents and materials to mention Herba Solani Lyrati, Herba Solani Lyrati water extract or Herba Solani Lyrati ethanol extract at present and can be used for hyperlipidemia.
Summary of the invention
The object of this invention is to provide the novelty teabag of Herba Solani Lyrati in preparation treatment hyperlipidemia medicine;
Another object of the present invention is to provide the novelty teabag of Herba Solani Lyrati water extract in preparation treatment hyperlipidemia medicine;
Another object of the present invention is to provide the preparation method of Herba Solani Lyrati water extract;
Another object of the present invention is to provide the novelty teabag of Herba Solani Lyrati ethanol extract in preparation treatment hyperlipidemia medicine;
Another object of the present invention is to provide the preparation method of Herba Solani Lyrati ethanol extract.
The object of the invention is by following technical scheme realize:
Crude drug source of the present invention:
Herba Solani Lyrati is the dry herb of plant of Solanaceae (SolanumlyratumThunb.), bitter in the mouth, cold nature, the ground such as main product Zhejiang, Jiangsu, Anhui.Herba Solani Lyrati has the history of more than 2000 year as Chinese medicine, has the effects such as heat-clearing and toxic substances removing, dispelling pathogenic wind and eliminating phlegm, expelling wind and removing dampness, is used for the treatment of malaria, jaundice, edema, gonorrhea, rheumatic arthritis, cholecystitis, cancer, cervical erosion, leucorrhea, furunculosis etc.
Inventor finds in the therapeutic process of research hyperlipidemia, Herba Solani Lyrati has reduction T-CHOL (totalcholesterol, TC), total triglyceride (totaltriglyceride, and low density lipoprotein, LDL (lowdensitylipoprotein TG), LDL) and simultaneously high density lipoprotein increasing (highdensitylipoprotein, HDL) effect, thus effectively can treat hyperlipidemia.Patent of the present invention is safe and effective in clinical practice, to can yet be regarded as a kind of good medicine in the Drug therapy for the treatment of hyperlipidemia, it has widened the scope of medication in treatment hyperlipidemia, the untoward reaction simultaneously for occurring when patient reduces conventional chemical drugs treatment hyperlipidemia.
Therefore, applicant provide Herba Solani Lyrati, Herba Solani Lyrati water extract, Herba Solani Lyrati ethanol extract be used for the treatment of/or prevention hyperlipidemia aspect novelty teabag.
The invention discloses the new opplication of Herba Solani Lyrati water extract for the preparation of hyperlipidemia medicine, the preparation of described Herba Solani Lyrati water extract comprises the following steps:
Get Herba Solani Lyrati, add medical material weight 6-10 water boil doubly and extract 1-3 time, first soak 10-30 minute before boiling for the first time, boil 1-3 hour, merge extractive liquid, at every turn, filter, filtrate concentrates, dry, obtains Herba Solani Lyrati water extract.
Preferably, the preparation of described Herba Solani Lyrati water extract comprises the following steps:
Get Herba Solani Lyrati, extracting in water twice, first time added medical material weight 8-10 water soaking doubly after 30 minutes, boiled extraction 2 hours, and second time adds medical material weight 6-8 water boil doubly and extracts 1 hour, merge extractive liquid, and filter, filtrate concentrates, dry, obtains Herba Solani Lyrati water extract.
The invention also discloses the application of Herba Solani Lyrati ethanol extract at preparation hyperlipidemia medicine, the preparation of described Herba Solani Lyrati ethanol extract comprises the following steps:
Get Herba Solani Lyrati, adding medical material weight 6-10 times percent by volume is the soak with ethanol of 30-95% after 30 minutes, heating and refluxing extraction 1-3 time, and each extraction time is 1-3 hour, merge extractive liquid, filters, and filtrate concentrates, dry, obtains Herba Solani Lyrati ethanol extract.Preferably, the preparation of described Herba Solani Lyrati ethanol extract comprises the following steps:
Get Herba Solani Lyrati, adding concentration is that 70% alcohol heating reflux extracts twice, and first time added the soak with ethanol of medical material weight 8 times after 30 minutes, extracted 2 hours, second time adds the ethanol extraction 1 hour of medical material weight 6 times, merge extractive liquid, filters, filtrate concentrates, dry, obtains Herba Solani Lyrati ethanol extract.
The Herba Solani Lyrati for the treatment of hyperlipemia of the present invention, Herba Solani Lyrati water extract, Herba Solani Lyrati alcohol extract, with pharmaceutically acceptable carrier combination, can make various common dosage forms, as tablet, granule, micropill, pill etc.
Pharmaceutically acceptable carrier of the present invention includes but not limited to following:
Diluent: starch, Icing Sugar, lactose, dextrin, microcrystalline Cellulose, inorganic salt, sugar alcohols etc.
Wetting agent and binding agent: purified water, ethanol, gelatin, Polyethylene Glycol, cellulose derivative etc.
Disintegrating agent: starch, carboxymethyl starch sodium, cellulose derivative, polyvinylpolypyrrolidone etc.
Lubricant: magnesium stearate, micropowder silica gel, Pulvis Talci, Polyethylene Glycol etc.
Cosolvent: water, ethanol, glycerol, propylene glycol, liquid Paraffin, plant wet goods.
Correctives: sucrose, monosaccharide, aromatic etc.
Antiseptic: benzoic acid, sorbic acid, methyl ester, ethyl ester, propyl ester etc.
Method 1: granule
Get Herba Solani Lyrati water extract or Herba Solani Lyrati alcohol extract, add granule and commonly use adjuvant, production method is prepared into granule of the present invention routinely.
Above-mentioned granule is commonly used adjuvant and is comprised one of diluent, wetting agent, binding agent or whole.
Method 2: tablet
Get Herba Solani Lyrati water extract or Herba Solani Lyrati alcohol extract, add tablet and commonly use adjuvant, production method is prepared into Tablets routinely.
Above-mentioned tablet is commonly used adjuvant and is comprised one of diluent, wetting agent, binding agent, disintegrating agent, lubricant or whole.
Method 3: micropill
Get Herba Solani Lyrati water extract or Herba Solani Lyrati alcohol extract, add micropill and commonly use adjuvant, production method is prepared into micropill of the present invention routinely.
Above-mentioned micropill is commonly used adjuvant and is comprised one of diluent, binding agent, lubricant or whole.
Above-mentioned chewable tablet is commonly used adjuvant and is comprised one of diluent, wetting agent, binding agent, lubricant or whole.
Method 4: pill
Get Herba Solani Lyrati water extract or Herba Solani Lyrati alcohol extract, add pill and commonly use adjuvant, production method is prepared into pill of the present invention routinely.
The novelty teabag that Herba Solani Lyrati provided by the invention, Herba Solani Lyrati water extract, Herba Solani Lyrati ethanol extract are used for the treatment of hyperlipidemia medicine aspect has the following advantages:
1, Herba Solani Lyrati, Herba Solani Lyrati water extract, Herba Solani Lyrati ethanol extract obtain, safety non-toxic from labiate Rabdosia lophanthoides plant Herba Solani Lyrati, can long-term taking.
2, animal data shows, medicine of the present invention is compared with chmice acute hyperlipidemia model group, blood lipid level obviously reduces (P < 0.01 or P < 0.05), wherein the present invention 80% ethanol extract, 95% ethanol extract difference very remarkable (P < 0.01) compared with hyperlipidemia model group.Compared with rat diet hyperlipidemia model group, blood lipid level obviously reduces (P < 0.01 or P < 0.05), and significantly reduce TC, TG, LDL level in rat blood serum, raising HDL levels (P < 0.05 or P < 0.01), wherein Herba Solani Lyrati 80% ethanol extract, Herba Solani Lyrati 95% ethanol extract difference very remarkable (P < 0.01) compared with hyperlipidemia model group.Illustrate that Herba Solani Lyrati water extract and ethanol extract all have effect for reducing blood fat, wherein 80% ethanol extraction, 95% ethanol extraction lipid-lowering effect optimum.
3, the extract Bloodlipid-lowering prepared with Herba Solani Lyrati is remarkable, and technique is simple, and Extraction solvent ethanol can recycle and reuse, and integrated cost is low, is a kind of novel lipid lowerers that can be used for long-term lipid-lowering therapy.
Detailed description of the invention
The present invention is further illustrated below by embodiment.It should be understood that embodiments of the invention are for illustration of the present invention instead of limitation of the present invention.Essence according to the present invention all belongs to the scope of protection of present invention to the simple modifications that the present invention carries out.Except as otherwise noted, the percent of the amount of alcohol in the present invention is percentage by volume, and v/v represents the volume ratio of solution.
Embodiment 1:
Get 10kg Herba Solani Lyrati to pulverize, extracting in water twice, first time added the water soaking of medical material weight 10 times after 30 minutes, boil extraction 2 hours, the water boil that second time adds medical material weight 6 times extracts 1 hour, merges extracted twice liquid, filter, filtrate concentrates, dry, obtains the dry cream of Herba Solani Lyrati water extract, add water for injection to dissolve, add syrup, benzoic acid, preparation becomes syrup.
Embodiment 2:
Get 10kg Herba Solani Lyrati to pulverize, extracting in water three times, first time added the water soaking of medical material weight 10 times after 30 minutes, boil extraction 3 hours, the water boil that second time adds medical material weight 8 times extracts 2 hours, and the water boil that third time adds medical material weight 6 times extracts 1 hour, merge three extracting solution, filter, filtrate concentrates, dry, obtain the dry cream of Herba Solani Lyrati water extract, add starch, microcrystalline Cellulose, sodium carboxymethyl cellulose, hypromellose sodium, magnesium stearate, Pulvis Talci, preparation becomes tablet according to a conventional method.
Embodiment 3:
Get 10kg Herba Solani Lyrati to pulverize, adding concentration is that 30% alcohol heating reflux extracts twice, first time added the soak with ethanol of medical material weight 10 times after 30 minutes, extracted 2 hours, added for the second time the ethanol extraction 1 hour of medical material weight 6 times, merge extractive liquid, filter, filtrate concentrates, vacuum drying, obtain the dry cream of Herba Solani Lyrati ethanol extract, add starch, refined honey preparation becomes honeyed pill.
Embodiment 4:
After getting the pulverizing of 10kg Herba Solani Lyrati, adding concentration is that 30% alcohol heating reflux extracts three times, and add medical material weight 10 times, 8 times, 6 times ethanol respectively, extraction time is respectively 3 hours, 2 hours, 1 hour at every turn, merge extractive liquid, filter, filtrate concentrates, dry, obtain the dry cream of Herba Solani Lyrati ethanol extract, pulverize, sieve, incapsulate and obtain capsule.
Embodiment 5:
Get 10kg Herba Solani Lyrati to pulverize, adding concentration is that 50% alcohol heating reflux extracts twice, and first time added the soak with ethanol of medical material weight 8 times after 30 minutes, extract 2 hours, second time adds the ethanol extraction 1 hour of medical material weight 6 times, merge extractive liquid, filters, filtrate concentrates, drying, obtains the dry cream of Herba Solani Lyrati ethanol extract, pulverizes, sieve, preparation becomes powder.
Embodiment 6:
Get 10kg Herba Solani Lyrati to pulverize, adding concentration is that 70% alcohol heating reflux extracts twice, and first time added the soak with ethanol of medical material weight 8 times after 30 minutes, extract 2 hours, second time adds the ethanol extraction 1 hour of medical material weight 6 times, merge extractive liquid, filters, filtrate concentrates, drying, obtains the dry cream of Herba Solani Lyrati ethanol extract, adds starch, microcrystalline Cellulose, sodium carboxymethyl cellulose, hypromellose sodium, magnesium stearate, Pulvis Talci, preparation becomes tablet according to a conventional method.
Embodiment 7:
After getting the pulverizing of 10kg Herba Solani Lyrati, adding concentration is that 80% alcohol heating reflux extracts twice, and first time added the soak with ethanol of medical material weight 8 times after 30 minutes, extract 2 hours, second time adds the ethanol extraction 1 hour of medical material weight 6 times, merge extractive liquid, filters, filtrate concentrates, drying, obtains the dry cream of Herba Solani Lyrati ethanol extract, adds starch, microcrystalline Cellulose, sodium carboxymethyl cellulose, hypromellose sodium, magnesium stearate, Pulvis Talci, preparation becomes tablet according to a conventional method.
Embodiment 8:
After getting the pulverizing of 10kg Herba Solani Lyrati, adding concentration is that 95% alcohol heating reflux extracts three times, and first time first soaks 30 minutes, add medical material weight 10 times, 8 times, 6 times ethanol respectively at every turn, extraction time is respectively 3 hours, 2 hours, 1 hour, merge extractive liquid, filters, filtrate concentrates, drying, obtains the dry cream of Herba Solani Lyrati ethanol extract, adds starch, microcrystalline Cellulose, sodium carboxymethyl cellulose, hypromellose sodium, magnesium stearate, Pulvis Talci, preparation becomes tablet according to a conventional method.
Effect experiment:
One, Herba Solani Lyrati extract is on the impact of acute hyperlipidemia level
1. experiment material
(1) animal
SPF level Kun Ming mice, robust half and half, body weight 20 ± 2g, buy from Guangxi Medical University's Experimental Animal Center (production licence number: SCXK osmanthus 2015-0002).
(2) medicine and instrument
Embodiment of the present invention 1-8 group, 0.9% normal saline (Pharmaceutical Group Co., Ltd of Nanning Baihui), Herba Solani Lyrati (Anhui Duo Shantang pharmaceutcal corporation, Ltd, fenofibrate, serum total cholesterol determination test kit, serum total triglyceride determination test kit, high density and low-density LP determination reagent box (SIGMA company), automatic clinical chemistry analyzer (manufacturer: step auspicious medical international corporation, model: BS-190).
2. experimental technique
Select healthy kunming mice 110, male and female half and half, be divided into 11 groups at random: blank, model comparison, positive controls, embodiment 1-8 group, often organize 10.
Each group of continuous gavage gives tested material 11d, gavage volume is 0.2ml/10g, positive controls gives fenofibrate, dosage is 100mg/kg, embodiment 1-8 group dosage is 200mg/kg, test 10d except blank group, all the other are respectively organized lumbar injection 75% egg yolk Emulsion (75% egg yolk normal saline suspension) 0.1mL/10g and carry out modeling.Before last gavage, water 12h is can't help in animal fasting, and after last gavage, 1h mice is plucked eyeball and gets blood, and the centrifugal 4min separation of serum of 3000r/min measures TC, TG value.
3. experimental result is in table 1.
The each tested material of table 1 on the impact of hyperlipidemia model lipid of mice level caused by Ovum Gallus domesticus album Emulsion ( n=10)
Note: compare with blank group, *p < 0.05, *p < 0.01; Compare with model control group, #p < 0.05, ##p < 0.01.
Table 1 result shows: acute hyperlipidemia model group mice serum T-CHOL and triglyceride are higher than blank group, and difference very significantly (P < 0.01); Positive controls, embodiment group are compared with hyperlipidemia model group, blood lipid level obviously reduces (P < 0.01 or P < 0.05), wherein the present invention 80% ethanol extract, 95% ethanol extract difference very remarkable (P < 0.01) compared with hyperlipidemia model group.The acute hyperlipidemia that Herba Solani Lyrati water extract and ethanol extract have certain prevention mice to answer diet Ovum Gallus domesticus album Emulsion to cause is described, wherein 80% ethanol extraction, 95% ethanol extraction lipid-lowering effect are optimum.
Two, Herba Solani Lyrati extract is on the impact of Diet hyperlipidemia blood lipid level.
1, experiment material
(1) animal
SD rat, male, body weight 180 ~ 210g, buys from Guangxi Medical University's Experimental Animal Center (production licence number: SCXK osmanthus 2009-0002).
(2) medicine and instrument
Embodiment of the present invention 1-8 group, 0.9% normal saline (Pharmaceutical Group Co., Ltd of Nanning Baihui), Herba Solani Lyrati (Anhui Duo Shantang pharmaceutcal corporation, Ltd, the total triglyceride determination test kit of serum total cholesterol determination test kit, serum, high density and low-density LP determination reagent box (SIGMA company), XUEZHIKANG JIAONANG (Beijing WBL Peking University Biotech Co., Ltd), automatic clinical chemistry analyzer (manufacturer: step auspicious medical international corporation, model: BS-190).
2, experimental technique
(1) the modeling phase: select healthy SD rat 110, male, rat is divided at random blank group (10), all the other are high fat group, two groups of rat body weight there was no significant difference (t=0.1132, P > 0.05), blank group gives normal diet, and high fat group gives high lipid food (79% normal feedstuff+1% cholesterol+10% yolk powder+10% Adeps Sus domestica).After 4 weeks, blank group and high fat group are randomly drawed 10 animals and are got orbital vein hematometry serum TC, TG, HDL, LDL, and as testing result height fat group is significantly higher than blank group, then rat hyperlipidemia model is formed.The results are shown in Table 2.
(2) experiment periods: be divided at random by 100 of high lipid food of feeding rats: model group, positive drug group, embodiment 1-8 group and positive drug group, often organizes 10 animals.The weight differences not statistically significant (F=0.2681, P > 0.05) of 10 groups of rats.
Within 5 weeks, be experiment periods after experiment, except blank group, all the other treated animals continue high lipid food of feeding, embodiment 1-8 group and positive drug group press scheme gavage every day, embodiment 1-8 group dosage is 200mg/kg, and positive drug group gives Xuezhikang, and dosage is 250mg/kg, the isopyknic normal saline of blank group gavage, gavage volume is 10ml/kg.At the end of experiment, Rat Fast can't help water 12h.Broken end gets blood, surveys the content of serum lipids.The results are shown in Table 3.
3, experimental result is in table 2, table 3..
Table 2 blank group and high fat group rat modeling phase lipids detection result
Note: compare with blank group, * * P < 0.01.
Table 2 result shows: TC, TG, HDL, LDL value of high fat group is all higher than blank group, and significant difference (P < 0.01), illustrates rat hyperlipidemia model modeling success.
The each tested material of table 3 is on the impact (x ± s, n=10) of rat fat
Note: compare with blank group, *p < 0.05, *p < 0.01; Compare with model control group, #p < 0.05, ##p < 0.01.
Table 2 result show: TC, TG, LDL value of high fat group all higher than blank group, HDL value lower than blank group, significant difference (P < 0.01).Compared with hyperlipidemia model group, positive drug group and embodiment group all significantly reduce TC, TG, LDL level in rat blood serum, raising HDL levels (P < 0.05 or P < 0.01), wherein Herba Solani Lyrati 80% ethanol extraction, Herba Solani Lyrati 95% ethanol extraction difference very remarkable (P < 0.01) compared with hyperlipidemia model group.Illustrate that Herba Solani Lyrati extract has significant effect for reducing blood fat, wherein 80% ethanol extraction, 95% ethanol extraction lipid-lowering effect optimum.
Experimental result shows: Herba Solani Lyrati water extract of the present invention and ethanol extract effectively can reduce the blood lipid level of hyperlipidemia model animal, wherein 80% ethanol extraction, 95% ethanol extraction lipid-lowering effect optimum.
4, discuss
Serum total cholesterol (TC), triglyceride (TG), low density lipoprotein, LDL (LDL) is higher all can cause hyperlipidemia, and high density lipoprotein (HDL) is the base substance of blood lipid metabolism, it is a kind of antiatherogenic plasma lipoprotein, there is the effect of removing the unnecessary blood fat of Ink vessel transfusing, removing blood dirt, cleaning blood vessel, be commonly called as " blood vessel street cleaner ".Animal data shows, medicine of the present invention is compared with hyperlipidemia model group, blood lipid level obviously reduces (P < 0.01 or P < 0.05), and significantly reduce TC, TG, LDL level in rat blood serum, raising HDL levels (P < 0.05 or P < 0.01), wherein Herba Solani Lyrati 80% ethanol extract, Herba Solani Lyrati 95% ethanol extract difference very remarkable (P < 0.01) compared with hyperlipidemia model group.Illustrate that Herba Solani Lyrati water extract and ethanol extract all have effect for reducing blood fat, wherein 80% ethanol extraction, 95% ethanol extraction lipid-lowering effect optimum.
Although above with general explanation, detailed description of the invention and test, the present invention is described in detail, and on basis of the present invention, can make some modifications or improvements it, this will be apparent to those skilled in the art.Therefore, these modifications or improvements without departing from theon the basis of the spirit of the present invention, all belong to the scope of protection of present invention.

Claims (9)

1. the novelty teabag of Herba Solani Lyrati in preparation treatment hyperlipidemia medicine.
2. the novelty teabag of Herba Solani Lyrati water extract in preparation treatment hyperlipidemia medicine.
3. novelty teabag according to claim 2, it is characterized in that described Herba Solani Lyrati water extract is prepared by following steps and obtains: get Herba Solani Lyrati, add medical material weight 6-10 water boil doubly to extract 1-3 time, first time first soaks 10-30 minute before boiling, and boils 1-3 hour, merge extractive liquid, at every turn, filter, filtrate concentrates, dry, obtains Herba Solani Lyrati water extract.
4. novelty teabag according to claim 2, it is characterized in that described Herba Solani Lyrati water extract is prepared by following steps and obtains: get Herba Solani Lyrati, extracting in water twice, first time added medical material weight 8-10 water soaking doubly after 30 minutes, boiled extraction 2 hours, second time adds medical material weight 6-8 water boil doubly and extracts 1 hour, merge extractive liquid, filters, and filtrate concentrates, drying, obtains Herba Solani Lyrati water extract.
5. the novelty teabag of Herba Solani Lyrati ethanol extract in preparation treatment hyperlipidemia medicine.
6. novelty teabag according to claim 5, it is characterized in that described Herba Solani Lyrati ethanol extract is prepared by following steps and obtains: get Herba Solani Lyrati, adding medical material weight 6-10 times percent by volume is that the soak with ethanol of 30-95% is after 30 minutes, heating and refluxing extraction 1-3 time, each extraction time is 1-3 hour, merge extractive liquid, filter, filtrate concentrates, dry, obtains Herba Solani Lyrati ethanol extract.
7. novelty teabag according to claim 5, it is characterized in that described Herba Solani Lyrati ethanol extract is prepared by following steps and obtains: get Herba Solani Lyrati, adding concentration is that 70% alcohol heating reflux extracts twice, and first time added the soak with ethanol of medical material weight 8 times after 30 minutes, extracted 2 hours, second time adds the ethanol extraction 1 hour of medical material weight 6 times, merge extractive liquid, filters, and filtrate concentrates, drying, obtains Herba Solani Lyrati ethanol extract.
8. novelty teabag according to claim 2, is characterized in that the application of Herba Solani Lyrati water extract at preparation treatment hyperlipidemia medicine.
9. novelty teabag according to claim 5, is characterized in that the application of Herba Solani Lyrati ethanol extract at preparation treatment hyperlipidemia medicine.
CN201610098221.6A 2016-02-23 2016-02-23 New application of solanum lyratum to preparation of medicine for treating hyperlipidemia Pending CN105560585A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610098221.6A CN105560585A (en) 2016-02-23 2016-02-23 New application of solanum lyratum to preparation of medicine for treating hyperlipidemia

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610098221.6A CN105560585A (en) 2016-02-23 2016-02-23 New application of solanum lyratum to preparation of medicine for treating hyperlipidemia

Publications (1)

Publication Number Publication Date
CN105560585A true CN105560585A (en) 2016-05-11

Family

ID=55871598

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610098221.6A Pending CN105560585A (en) 2016-02-23 2016-02-23 New application of solanum lyratum to preparation of medicine for treating hyperlipidemia

Country Status (1)

Country Link
CN (1) CN105560585A (en)

Similar Documents

Publication Publication Date Title
US20210235716A1 (en) Stable ready-to-drink beverage compositions comprising lipophilic active agents
US20180117161A1 (en) Methods for formulating orally ingestible compositions comprising lipophilic active agents
CN105395919B (en) It is a kind of to contain black fungus extract, the composition with effect for reducing blood fat and preparation method thereof
CN104041896A (en) Medicine and food homologous plant concentrated juice and preparation method thereof
EP2040726A1 (en) Trachelospermi caulis extract composition for the treatment and prevention of inflammatory diseases
CN104940284A (en) Novel application of rabdosia lophanthide in preparing hyperlipidaemia treating and/or preventing medicine
CN109528848A (en) A kind of pharmaceutical composition and the preparation method and application thereof preventing and treating alcoholic liver injury
US9186387B2 (en) Method of treating fatty liver disease
CN110072517A (en) The method for treating the viral hepatitis type b that how there is drug resistance to liver
CN102068557B (en) Application of Pu&#39;er tea extract in preparation of medicines for reducing blood fat
CN1558768A (en) A pharmaceutical composition made from Chinese traditional medicine and preparation method thereof
CN105456550B (en) Gastric mucosa damage prophylactic treatment compound and the preparation method and application thereof
CN104922178B (en) Hypoglycemic effervescent tablet and application thereof
CN105287685A (en) Application of alcohol extract of viburnum sargentii koehne to preparation of medicines for treating atherosclerosis diseases
CN105560585A (en) New application of solanum lyratum to preparation of medicine for treating hyperlipidemia
JP2004352626A (en) Anticholesterol agent containing plant-derived component
JP2008007473A (en) Cassia obtusifolia l. or cassia tora l. seed extract
CN107048108A (en) A kind of preparation method of alkalescent licorice drink
CN105520971A (en) New application of dolac in preparation of medicine for treating and/or preventing hyperlipidemia
CN105193993B (en) A kind of Chinese medicine composition with blood fat reducing function and preparation method thereof and purposes
CN110038043A (en) A kind of pueraria lobata toxin expelling nutrient powder and its preparation method and application
CN103432541A (en) Novel application of Zingiber mioga bud extractive in blood fat reduction
CN104127545B (en) New application of murraya tetramera huang and extract thereof in preparation of medicines
CN109481481B (en) Preparation method and application of chimonanthus salicifolius total flavone extract
CN105535104A (en) New application of cassytha filiformis to preparation of medicine for treating and/or preventing hyperlipemia

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20160511